SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks -- Ignore unavailable to you. Want to Upgrade?


To: El Canadiense who wrote (41534)4/14/2016 12:18:50 PM
From: ayeyou  Respond to of 49402
 
It was my , perhaps incorrect, belief that Pepsico was interested in producing a booster type health drink with the avenathramides from CZO as well as the oatmeal cookie and cereal aspect. Either way its big biz for CZO if it comes to fruition. Certainly seems like a natural fit for Quaker Oats who have championed the health aspects of oats for decades.

Ceapro has the ability to produce a supplement or other food ingredient carrying the power of refined oat/aavenathramide, which of course has huge implications for nutrition. “I truly believe that avenahtramides are going to be probably bigger than beta glucan was back in the eighties,” Fielder states. In fact food-giant Quaker Oats (a division of PepsiCo Frito Lay) has petitioned the US Food and Drug Authority for approval to make health benefit claims for the avenathramide content of oats – a claim which earlier had been approved in Europe. “I think it’s very exciting, says Fielder,” Because while we’re focused on the cosmetic and personal care industry right now – dermatology specifically – we see lots of new potential markets opening up for us.” Ceapro signed an agreement with Agriculture Canada earlier this year to use an avenathramide extraction process developed by now retired scientist Bill Collins and is in the midst of a pilot project application. If that proves successful, Fielder can see Ceapro moving into food industry applications. Ceapro technology may cross over to other applications – such as extractions from different plant sources. For example, The company has done extraction from a mint plant variety, as well as from a sweet blue lupin, also for the cosmetic industry. In other words the company grows, Ceapro may well branch out into other botanical ingredients – particularly those with “actives’ which may have beneficial therapeutic benefits. Compared to the food industry, Ceapro actually processes a relatively small amount of oat material, so they work mostly with “niche growers” for very specific varieties But the technology has great potential for work in the area of functional foods, Fielder says. Many companies that produce neutriceuticals and supplements may use oat extract in their products because the overwhelming 7 health benefits, Fielder explains. At some point, having the right strategic partner in the food industry could create opportunity for larger volumes from Ceapro.

poga.ca